MB-11362

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H27ClN5O11P
Molecular Weight	627.925
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)O[C@H]1[C@@H](O[C@@](CO[P@@]2(=O)OCC[C@H](O2)C3=CC(Cl)=CC=C3)(N=[N+]=[N-])[C@H]1OC(=O)CC)N4C=CC(=O)NC4=O

InChI

InChIKey=DOIJDQFWSCXUHP-FWWVIJAESA-N

InChI=1S/C24H27ClN5O11P/c1-3-18(32)38-20-21(39-19(33)4-2)24(28-29-26,40-22(20)30-10-8-17(31)27-23(30)34)13-37-42(35)36-11-9-16(41-42)14-6-5-7-15(25)12-14/h5-8,10,12,16,20-22H,3-4,9,11,13H2,1-2H3,(H,27,31,34)/t16-,20+,21-,22+,24+,42+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H27ClN5O11P
Molecular Weight	627.925
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:14:56 GMT 2023` Edited by `admin` on `Sat Dec 16 10:14:56 GMT 2023`
Record UNII	3QJ8NSS2G9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MB-11362

Code

English

MB11362

Code

English

URIDINE, 4'-C-AZIDO-5'-O-(4-(3-CHLOROPHENYL)-2-OXIDO-1,3,2-DIOXAPHOSPHORINAN-2-YL)-, 2',3'-DIPROPANOATE

Systematic Name

English

RG-7348

Common Name

English

((2R,3R,4S,5R)-5-(((2R,4S)-4-(3-CHLOROPHENYL)-2-OXO-1,3,2'L-5'-DIOXAPHOSPHINAN-2-YL)OXYMETHYL)-2-(2,4-DIOXOPYRIMIDIN-1-YL)-5-((IMINO-L-5'-AZANYLIDENE)AMINO)-4-PROPANOYLOXY-TETRAHYDROFURAN-3-YL) PROPANOATE

Systematic Name

English

Code System Code Type Description

FDA UNII

3QJ8NSS2G9

Created by admin on Sat Dec 16 10:14:56 GMT 2023 , Edited by admin on Sat Dec 16 10:14:56 GMT 2023

PRIMARY

CAS

1159183-97-7

Created by admin on Sat Dec 16 10:14:56 GMT 2023 , Edited by admin on Sat Dec 16 10:14:56 GMT 2023

PRIMARY

PUBCHEM

42623239

Created by admin on Sat Dec 16 10:14:56 GMT 2023 , Edited by admin on Sat Dec 16 10:14:56 GMT 2023

PRIMARY

Related Record Type Details


					3QJ8NSS2G9

MB-11362

ACTIVE MOIETY

Comments:

Originator: Ligand Pharmaceuticals, Roche; Class: Antiviral; Mechanism of Action: Undefined mechanism; Highest Development Phase: Phase I for Hepatitis C; Most Recent Event: 21 Apr 2010 Phase-I clinical trials in Hepatitis C in USA (unspecified route)